ArticleCancer discovery2019
Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling.
Abstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it, 180 citations in OpenAlex.
- Preclinical efficacy and mechanisms of statin-loaded polymeric nanocapsules: a meta-analysis of tumor lipid metabolism inhibition.Scientific reports · 2025Pooled it
- Review
- Fatty acid metabolism in glioma: a review of novel targets and therapeutic strategies.Chinese neurosurgical journal · 2026Review
- Co-overexpression of ELOVL2 and ELOVL5 promotes clear cell renal cell carcinoma progression through LIMK1-mediated cytoskeletal reorganization.Scientific reports · 2026Article
- Super-Enhancer-Associated Gene 3-Hydroxybutyrate Dehydrogenase 1 Increases Intramuscular Fat Deposition of Yaks (Foods (Basel, Switzerland) · 2026Article
- Super-enhancer-driven TCF4 orchestrates neuroblastoma metastasis by sphingolipid-dependent membrane remodeling and ITGB1-FAK activation.Neuro-oncology · 2026Article
- Adenylate kinase 4 promotes radioresistance by suppressing radiation-induced ferroptosis through metabolic regulation in glioblastoma.Apoptosis : an international journal on programmed cell death · 2026Article
- Glioblastoma stem cells resist cuproptosis with circadian variation of copper levels.The Journal of clinical investigation · 2026Article
- Tumor organoids for testing metabolic flexibility in precision oncology.Frontiers in oncology · 2026Review
- Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks.Frontiers in oncology · 2026Review
- CDK12 regulates cellular metabolism to promote glioblastoma growth.JCI insight · 2025Article
- RUNX2 cooperates with SREBP1 to rewire cancer metabolism and promote aggressiveness.Journal of experimental & clinical cancer research : CR · 2025Article
- Nanoneedles enable spatiotemporal lipidomics of living tissues.Nature nanotechnology · 2025Article
- Melatonin Inhibiting Neuronal Cells Ferroptosis Through Lipid Metabolic Reprogramming.Molecular neurobiology · 2025Article
- Differentiation, ageing and leukaemia alter the metabolic profile of human bone marrow haematopoietic stem and progenitor cells.Nature cell biology · 2025Article
- Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal transduction and targeted therapy · 2025Review
- Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review.International journal of molecular sciences · 2025Article
- The multilayered transcriptional architecture of glioblastoma ecosystems.Nature genetics · 2025Article
- Increased Immune Infiltration and Improved Prognosis of Head and Neck Squamous Cell Carcinoma Associated with Reduced Ancient Ubiquitous Protein 1 Gene Expression.Molecular biotechnology · 2025Article
- Targeting ELOVL6 to disrupt c-MYC driven lipid metabolism in pancreatic cancer enhances chemosensitivity.Nature communications · 2025Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 7 institutions in 3 countries.
Ryan C GimpleDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-7189-3243
Reilly L KidwellDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Leo J Y KimDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-1790-9136
Tengqian SunSalk Institute for Biological Studies, La Jolla, California.
Anthony D GromovskyDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Qiulian WuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Megan WolfDepartment of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
Deguan LvDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0003-3142-9814
Shruti BhargavaDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Li JiangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Briana C PragerDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Xiuxing WangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-5993-9368
Qing YeSalk Institute for Biological Studies, La Jolla, California.
Zhe ZhuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-5385-948X
Guoxin ZhangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Zhen DongDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Linjie ZhaoDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Derrick LeeDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Junfeng BiLudwig Institute for Cancer Research, University of California, San Diego, La Jolla, California.
Andrew E SloanCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland Ohio.
Paul S MischelLudwig Institute for Cancer Research, University of California, San Diego, La Jolla, California.
J Mark BrownDepartment of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
Hu CangSalk Institute for Biological Studies, La Jolla, California.
Tao HuanDepartment of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
Stephen C MackDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas.
Qi XieDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California. jerich@ucsd.edu xieqi@westlake.edu.cn.
Jeremy N RichDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California. jerich@ucsd.edu xieqi@westlake.edu.cn.
University of California San Diego · USSalk Institute for Biological Studies · USCleveland Clinic Lerner College of Medicine · USUniversity of British Columbia · CABaylor College of Medicine · USUniversity Hospitals of Cleveland · USWestlake University · CN
Funding
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3MClinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0MClinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MProject Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Thomas M McIntyre · 2016 to 2026
$19.6MDynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4MThe role of mTORC2 in reprogramming cancer cell metabolismR01NS073831 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MISCHEL, PAUL S · 2011 to 2020
$3.4MA Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain TumorsR01CA217956 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BRADY-KALNAY, SUSANN M, GASTINEAU, EDWARD · 2017 to 2021
$3.4MUltra Sensitive Single Molecule Spectroscopy With Plasmonic AntennasDP2EB020400 · NIBIB · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI CANG, HU · 2014 to 2014
$2.9MTargeting Ferritin in GlioblastomaR01CA169117 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI BAO, SHIDENG, CONNOR, JAMES ROBERT · 2013 to 2017
$2.7MMetabolism Informs Intertumoral & Intratumoral HeterogeneityR01NS087913 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NAKANO, ICHIRO, RICH, JEREMY N · 2014 to 2018
$2.0MEnzymatic Control of Trimethylamineoxide (TMAO)Induced AtherosclerosisR01HL122283 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BROWN, JONATHAN MARK · 2014 to 2018
$2.0MNCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR002548NCI NIH HHS F30 CA203101NCI NIH HHS F30 CA217065NCI NIH HHS F30 CA217066NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA154130NCI NIH HHS R01 CA169117NCI NIH HHS R01 CA171652NCI NIH HHS R01 CA187780NCI NIH HHS R01 CA217956NCI NIH HHS R35 CA197718NHLBI NIH HHS R01 HL122283NIAAA NIH HHS P50 AA024333NIBIB NIH HHS DP2 EB020400NIGMS NIH HHS T32 GM007250NINDS NIH HHS R01 NS073831NINDS NIH HHS R01 NS087913NINDS NIH HHS R01 NS089272NINDS NIH HHS R01 NS103434
Abstract
Glioblastoma ranks among the most aggressive and lethal of all human cancers. Functionally defined glioma stem cells (GSC) contribute to this poor prognosis by driving therapeutic resistance and maintaining cellular heterogeneity. To understand the molecular processes essential for GSC maintenance and tumorigenicity, we interrogated the superenhancer landscapes of primary glioblastoma specimens and
Indexed as
Enhancer Elements, GeneticAnimalsBrain NeoplasmsCell Line, TumorCell ProliferationEpigenesis, GeneticErbB ReceptorsFatty Acid ElongasesFatty Acids, UnsaturatedGene Expression Regulation, NeoplasticGlioblastomaHistonesHumansMethylationNeoplastic Stem CellsSignal TransductionEGFR protein, humanELOVL2 protein, humanErbB ReceptorsFatty Acid ElongasesFatty Acids, UnsaturatedHistonesSOX2 protein, humanSOXB1 Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.